Tag: Humabody

May 5, 2020 Off

Crescendo, Cancer Research UK to develop novel bispecific Humabody therapeutic

Cancer Research UK’s Centre for Drug Development will fund Phase I clinical trial in solid tumours, Crescendo’s novel bispecific Humabody immunotherapies, CB213.

September 24, 2019 Off

Crescendo Biologics reaches another milestone in its deal with Takeda

By BusinessWire

Crescendo Biologics has reached fifth milestone in its deal with Takeda from 2016, for using its Humabody-based therapeutics against targets which Takeda selects.